Abstract
The new antipsychotic drug setoperone is pharmacologically characterized by its potent serotonin and moderate dopamine receptor blocking properties. Forty chronic schizophrenic patients were included and 34 completed this pilot study. Following a drug free period of 1 week the patients received setoperone 5 mg t.i.d. After 1 month of treatment, the psychotic symptoms, as measured by the BPRS, improved by approximately 50% (P<0.001) as compared with the condition under previous neuroleptic medication. Blockade of serotonin receptors may be related to improvement of autistic behaviour, dysphoria, and parkinson-like symptoms. In residual schizophrenic patients, the need for dopamine blockade, which is normally correlated with the therapeutic effect on positive symptoms, can be reduced substantially.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ceulemans D, Hoppenbrouwers ML, Gelders Y, Reyntjens A (1984a) Serotonin blockade or benzodiazepine? What kind of anxiolysis? Collegium Internationale Neuro-Psychopharmacologicum, 14th C.I.N.P. Congress. Abstracts, 727
Ceulemans D, Gelders Y, Hoppenbrouwers ML, Reyntjens A (1984b) Does serotonin blockade compensate for dopamine insufficiency in extrapyramidal symptoms. Collegium Internationale Neuro-Psychopharmacologicum, 14th C.I.N.P. Congress. Abstracts, 309
Cheshire RM, Jung Tung Cheng, Teitelbaum Ph (1982) Antiserotonergic drugs reinstate galloping forward locomotion produced by pontine tegmentum damage in rats. In: Beng Tho, Schoolar JC, and Usdin E (eds) Serotonin in biological psychiatry, vol. 34, Raven Press, New York, pp 315–317
Crow TJ (1980) Molecular pathology of schizophrenia: more than one disease process? Br Med J 280:66–68
DeLisi LE, Neckers LM, Weinberger DR, Wyatt RJ (1981) Increased whole blood serotonin concentrations in chronic schizophrenic patients. Arch Gen Psychiatr 38:647–650
Geller E, Ritvo ER, Freeman BJ, Yuwiler A (1982) Preliminary observations in the effect of fenfluramine on blood serotonin and symptoms in three autistic boys. New Engl J Med 307:165–168
Meltzer HY, Stahl SM (1976) The dopamine hypothesis of schizophrenia: a review. Schizophr Bull 2:19–76
Niemegeers CJE, Leysen JE, Laduron PM, Janssen PAJ (1984a) Differential pharmacological and biochemical profiles of serotonin-S2 antagonists. Collegium Internationale Neuro-Psychopharmacologicum, 14th C.I.N.P.-Congress, Abstracts, 667
Niemegeers CJE, Awouters F, Janssen PAJ (1984b) Setoperone (R 52 245) a new type of neuroleptic. Collegium Internationale Neuro-Psychopharmacologicum, 14th C.I.N.P. Congress, Abstracts 814
Overall JE, Gorham DR (1962) The Brief Psychiatric Rating Scale. Psychol Rep 10:799–812
Peroutka SJ, Snyder SH (1980) Regulation of serotonin2 (5-HT2) receptors labeled with (3H)spiroperidol by chronic treatment with the antidepressant amitriptyline. J Pharmacol Exp Ther 215:525–587
Pöldinger W, Sieberns S (1983) Depression-inducing and antidepressive effects of neuroleptics, Experiences with flupenthixol and flupenthixol decanoate. Neuropsychobiology 10:131–136
Simpson GM, Angus JWS (1970) A rating scale for extrapyramidal side-effects. Acta Psychiatr Scand 212:11–19
van Wielinck PS, Leysen JE (1983) Farmacologische keuzecriteria voor neuroleptica. J Drug Res 8:1984–1997
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ceulemans, D.L.S., Gelders, Y.G., Hoppenbrouwers, ML.J.A. et al. Effect of serotonin antagonism in schizophrenia: A pilot study with setoperone. Psychopharmacology 85, 329–332 (1985). https://doi.org/10.1007/BF00428197
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00428197